Teleflex (TFX) AI Stock Analysis

• Market Cap: $5.70B
• Dividend Yield: 1.04%
• Average Volume (3M): 557.57K
• Price to Earnings (P/E): 30.4
• Beta (1Y): 0.70
• Revenue Growth: 1.11%
• EPS Growth: -23.73%
• Country: US
• Employees: 14,100
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.73
• Shares Outstanding: 44,192,818
• 10 Day Avg. Volume: 554,417
• 30 Day Avg. Volume: 557,567
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: 2.31
• Enterprise Value/Gross Profit: 4.15
• Enterprise Value/Ebitda: 14.00
• 1Y Price Target: $136.80
• Price Target Upside: 4.67% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 73 Outperform
• Price Target: $132.00 ▲(0.99% Upside)

Teleflex's overall stock score is driven by strong financial performance and positive earnings call outcomes, highlighting strategic acquisitions and improved guidance. Technical analysis and valuation present mixed signals, with moderate technical strength and a relatively high P/E ratio. Despite some challenges, the company's strategic initiatives and financial health position it well for future growth.

Positive Factors

Acquisition Impact

TFX completed its acquisition of Biotronik's Vascular Intervention business, expanding its branded product portfolio and providing growth opportunities.

Revenue Estimates

Revenue estimates are raised to account for revenue from the acquisition deal, indicating potential for increased financial performance.

Shareholder Value

The separation will reduce the number of RemainCo manufacturing facilities, simplifying the business and unlocking shareholder value.

Negative Factors

Growth Visibility

Limited visibility into post-acquisition, post-spin financials is expected to limit nearer-term share price appreciation.

Operating Margins

TFX's gross margin was down 70 bps Y/Y and operating margin was down 190 bps Y/Y, affecting profitability.

Tariff Impact

The tariff situation is too volatile, and TFX is not updating its guidance, indicating uncertainty in future financial impacts.

Teleflex Business Overview & Revenue Model

Company Description

Teleflex Incorporated (TFX) is a global provider of medical technologies designed to improve the health and quality of people's lives. The company operates in various sectors, including vascular access, anesthesia, respiratory care, and surgical devices. Teleflex offers a wide range of products, including catheters, surgical instruments, and devices for managing airway and vascular access, focusing on innovation and high-quality outcomes for healthcare professionals and patients.

How the Company Makes Money

Teleflex generates revenue primarily through the sale of its medical devices and products across different healthcare sectors. The company has a diversified revenue model that includes direct sales to healthcare providers, hospitals, and other medical institutions. Key revenue streams include vascular access products, anesthesia products, and surgical instruments. Additionally, Teleflex benefits from strategic partnerships and collaborations with healthcare organizations and distributors, which enhance its market reach and product availability. The company's focus on innovation and development of new products also contributes significantly to its earnings, as it meets the evolving needs of the healthcare market.

Teleflex Financial Statement Overview

Summary

Teleflex demonstrates solid financial health with strong profitability, stable revenue growth, and impressive cash flow management. The balance sheet is robust with low leverage and a strong equity position, indicating sustained financial stability and growth potential.

Income Statement

Teleflex shows strong profitability with a Gross Profit Margin of 55.7% and Net Profit Margin of 5.0% in TTM. Revenue grew modestly at 0.6% from the previous year, indicating stable growth. Notably, the EBITDA Margin stands at 15.9%, reflecting healthy operational efficiency. However, the EBIT Margin is somewhat lower at 8.6%, suggesting some operational cost challenges.

Balance Sheet

The company maintains a solid financial structure with a Debt-to-Equity Ratio of 0.05, indicating low leverage. The Return on Equity is 3.6% in TTM, which is moderate but could be improved. The Equity Ratio is robust at 57.2%, showcasing a strong equity base. Overall, the balance sheet is stable with manageable debt levels.

Cash Flow

Teleflex exhibits strong cash flow management, with a Free Cash Flow to Net Income Ratio of 3.41 in TTM, indicating efficient cash generation relative to earnings. The Operating Cash Flow to Net Income Ratio is 4.00, highlighting strong cash conversion. Free Cash Flow has grown slightly by 0.2% from the previous year, maintaining positive cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.04B	3.05B	2.97B	2.79B	2.81B	2.54B
Gross Profit	1.69B	1.70B	1.65B	1.53B	1.55B	1.32B
EBITDA	501.68M	452.66M	761.21M	751.65M	873.10M	665.98M
Net Income	191.93M	69.67M	356.33M	363.14M	485.37M	335.32M
Balance Sheet
Total Assets	7.38B	7.10B	7.53B	6.93B	6.87B	7.15B
Cash, Cash Equivalents and Short-Term Investments	253.70M	290.19M	222.85M	292.03M	445.08M	375.88M
Total Debt	2.00B	1.76B	1.93B	1.83B	1.97B	2.56B
Total Liabilities	3.13B	2.82B	3.09B	2.91B	3.12B	3.82B
Stockholders Equity	4.24B	4.28B	4.44B	4.02B	3.75B	3.34B
Cash Flow
Free Cash Flow	431.42M	509.31M	419.20M	262.95M	579.80M	345.71M
Operating Cash Flow	514.63M	635.74M	510.64M	342.14M	651.42M	436.41M
Investing Cash Flow	-56.02M	-99.36M	-621.23M	-257.94M	156.74M	-837.78M
Financing Cash Flow	-353.46M	-421.93M	38.54M	-217.51M	-715.82M	455.16M

Teleflex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 130.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Positive. The current price of 130.7 is above the 20-day moving average (MA) of 124.55, above the 50-day MA of 119.50, and below the 200-day MA of 143.72, indicating a neutral trend. The MACD of 2.92 indicates Negative momentum. The RSI at 63.99 is Neutral, neither overbought nor oversold. The STOCH value of 71.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TFX.

Teleflex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	$5.51B	47.23	8.60%	―	10.14%	0.04%
LMAT	76 Outperform	$2.20B	47.14	13.81%	0.78%	14.11%	23.98%
TFX	73 Outperform	$5.70B	30.39	4.36%	1.04%	1.11%	-23.73%
HAE	68 Neutral	$2.61B	16.60	18.27%	―	0.91%	45.81%
BLCO	55 Neutral	$5.16B	―	-4.22%	―	8.81%	40.43%
ICUI	53 Neutral	$3.10B	―	-1.78%	―	2.95%	47.92%
Sector *	51 Neutral	$7.95B	-0.40	-41.67%	2.21%	22.29%	-1.85%

Teleflex Corporate Events

Teleflex Raises 2025 Guidance After BIOTRONIK Acquisition

Teleflex reported its financial results for the second quarter ending June 29, 2025, with a GAAP revenue increase of 4.2% compared to the previous year. The company’s adjusted diluted EPS also rose to $3.73 from $3.42. Teleflex raised its full-year 2025 revenue and EPS guidance, reflecting the impact of its recent acquisition of BIOTRONIK’s Vascular Intervention business. This acquisition is expected to strengthen Teleflex’s global footprint in the peripheral intervention market, complementing its existing portfolio and supporting its value creation strategy.